Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC

New England Journal of Medicine

Volumn 378, Issue 24, 2018, Pages 2288-2301

  Socinski, M A ^a   Jotte, R M ^b,c   Cappuzzo, F ^d   Orlandi, F ^e   Stroyakovskiy, D ^f   Nogami, N ^g   Rodriguez Abreu, D ^h   Moro Sibilot, D ⁱ   Thomas, C A ^k   Barlesi, F ^j   Finley, G ^l   Kelsch, C ^m   Lee, A ^m   Coleman, S ^m   Deng, Y ^m   Shen, Y ^m   Kowanetz, M ^m   Lopez Chave, A ^m   Sandler, A ^m   Reck, M ^n,o  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b ROCKY MOUNTAIN CANCER CENTERS   (United States)

^c US Oncology Research   (United States)

^d Dermatology Unit   (Italy)

^e INSTITUTO NACIONAL DEL TÓRAX   (Chile)

^f D Rogachev Federal Research Center of Pediatric Hematology Oncology and Immunology   (Russian Federation)

^g NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^h HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j AIX MARSEILLE UNIVERSITY   (France)

^k New England Cancer Specialists   (United States)

^l ALLEGHENY HEALTH NETWORK   (United States)

^m GENENTECH INC   (United States)

ⁿ Mitglied im DZL   (Germany)

^o GERMAN CENTER FOR LUNG RESEARCH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ATEZOLIZUMAB; BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; VASCULOTROPIN A;

ADULT; AGED; ALK GENE; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER MORTALITY; COLITIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG SAFETY; EFFECTOR CELL; EGFR GENE; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE; GENE EXPRESSION; GENOTYPE; HAZARD RATIO; HEMOPTYSIS; HEPATITIS; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; INTENTION TO TREAT ANALYSIS; LIVER METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PARESTHESIA; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; WILD TYPE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; IMMUNOTHERAPY; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROTO ONCOGENE; SECONDARY; SURVIVAL ANALYSIS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7-H1 ANTIGEN; BEVACIZUMAB; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, ERBB-1; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PACLITAXEL; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85048771306     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1716948     Document Type: Article

References (38)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
2. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: Suppl 5: v1-v27.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Vol. 2. 2018 (https://www .nccn .org/professionals/physician-gls/PDF/nscl .pdf).
4. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-smallcell lung cancer. N Engl J Med 2016; 375: 1823-33.
5. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078-92.
6. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed deathligand 1 and programmed death-1. Clin Cancer Res 2012; 18: 6580-7.
7. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7.
8. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-smallcell lung cancer (OAK): A phase 3, openlabel, multicentre randomised controlled trial. Lancet 2017; 389: 255-65.
9. Liu SV, Camidge DR, Gettinger SN, et al. Atezolizumab (atezo) plus platinumbased chemotherapy (chemo) in non-small cell lung cancer (NSCLC): update from a phase Ib study. J Clin Oncol 2017; 35: Suppl 15: 9092. abstract.
10. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39.
11. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387: 1540-50.
12. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27: 1227-34.
13. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as firstline therapy for nonsquamous non-smallcell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-9.
14. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
15. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996; 170: 101-10.
16. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160: 1224-32.
17. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-121.
18. Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607-15.
19. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2: 632-42.
20. Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016; 7: 12624.
21. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 2016; 27: 1492-504.
22. Gabrilovich DI, Nagaraj S. Myeloidderived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
23. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009; 4(11): e7669.
24. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-30.
25. Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015; 212: 139-48.
26. Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 2017 December 8 (Epub ahead of print).
27. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013; 39: 1-10.
28. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-46.
29. Kowanetz M, Zou W, McCleland M, et al. Pre-existing immunity measured by Teff gene expression in tumor tissue is associated with atezolizumab efficacy in NSCLC. J Thorac Oncol 2017; 12: Suppl 2: S1817-S1818. abstract.
30. Dmitrienko A, Huque MF. Key multiplicity issues in clinical drug development. Stat Med 2013; 32: 1079-111.
31. Dmitrienko A, Traditional multiplicity adjustment methods in clinical trials. Stat Med 2013; 32: 5172-218.
32. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91.
33. Gadgeel S, Kowanetz M, Zou W, et al. Clinical efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK study. Ann Oncol 2017; 28: Suppl 5: 460-1. abstract.
34. Pillai RN, Kamphorst AO, Owonikoko TK, et al. Liver metastases and sensitivity to checkpoint inhibition in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2016; 34(15): Suppl: e20665
35. Tumeh PC, Hellmann MD, Hamid O, et al. Liver metastasis and tr7eatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 2017; 5: 417-24.
36. Paz-Ares LG, Shen K, Higgs BW, et al. Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials. J Clin Oncol 2017; 35(15): Suppl: 3038.
37. Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017; 35: 2781-9.
38. Cortinovis D, von Pawel J, Syrigos K, et al. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: safety population analyses from the Ph III study OAK. Ann Oncol 2017; 28: Suppl 5: 468. abstract.